Bicara Therapeutics Inc. (BCAX) Institutional Ownership & Insider Trading

171 institutions reported holding Bicara Therapeutics Inc. shares in 13F filings for the quarter ended 2026-06-30, according to EquiReason's reading of their SEC filings. 72 insider trades on Form 4 since 2025-10-01.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

BCAXBicara Therapeutics Inc.Follow BCAX — free

Biotechnology · Healthcare

—

Price chart with a free account

Market cap: 1.1B
P/E TTM: —
Dividend yield: —
52-week: —
Next earnings: 17 Nov, in 24 days

Institutions · all 13F filers

quarter to 30 Jun 2026 · filers in both quarters

171 institutions held —% of the shares. Across filers that reported both quarters, shares held changed +3.2%.

Largest moves, shares (millions)

Institutional flow by quarter

net shares added or trimmed, millions · filers in both quarters

Quarter	Holders	Shares held, M	Change	Increased	New	Decreased	Closed
Jun 26	171	70	+3.2%	63	34	34	7
Mar 26	145	70	+17.8%	52	21	38	20
Dec 25	139	57	+14.1%	42	42	29	17
Sep 25	111	50	-1.4%	38	24	23	13
Jun 25	105	51	+5.6%	43	32	15	18
Mar 25	92	49	+4.4%	24	27	16	16
Dec 24	83	47	+16.1%	22	31	5	23
Sep 24	68	36	—	—	—	—	—

Bicara Therapeutics Inc. — questions

Who owns Bicara Therapeutics Inc. stock?: 171 institutions reported Bicara Therapeutics Inc. shares in 13F filings for the quarter ended 2026-06-30. The largest: RA CAPITAL MANAGEMENT, L.P. (11.0%), T. Rowe Price Investment Management, Inc. (9.6%), Siren, L.L.C. (8.5%).
Are Bicara Therapeutics Inc. insiders buying or selling?: 72 insider trades on Form 4 since 2025-10-01; the full list, with dates, people and plan status, is on this page.

Every figure on this page comes from Bicara Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.

Important information. Figures on this page are taken from filings submitted to the U.S. Securities and Exchange Commission (SEC) and processed automatically by EquiReason. They may contain errors, omissions or delays, and EquiReason makes no representation or warranty as to their accuracy, completeness or timeliness. Always verify figures against the original filing on SEC EDGAR before relying on them.

This page is provided for general information and educational purposes only. It does not constitute investment, financial, legal or tax advice, and it is not a recommendation or an offer to buy, sell or hold any security. It does not take into account your objectives, financial situation or needs. Past performance does not guarantee future results; any reliance on this information is at your own risk. See our Disclaimer and Risk Disclosure.